The Problem
Pathogen reporting can often be delayed or inaccurate, leaving locally trained health professionals unable to diagnose dangerous viruses that present with fever, aches and nausea, which are all common symptoms for Zika, Malaria and the Flu.
Global health surveillance is essential, providing vital data on disease incidence and drug resistance. However, data collection can be a sizeable undertaking, placing an additional burden on already stretched – and often under resourced – healthcare professionals.
“One important finding of the report, which will serve as a baseline to measure future progress, is that there are many gaps in information on pathogens of major public health importance.
In addition, surveillance of antibiotic resistance generally is neither coordinated nor harmonised, compromising the ability to assess and monitor the situation.”
WHO AMR Global Report
Our Solution
Imagine being able to contain an outbreak of a novel virus before it became a global epidemic.
Imagine the world’s healthcare systems were one step ahead of antibiotic resistance.
Imagine researchers had the data they need to develop and test novel disease management interventions.
The connectivity of globally distributed Q-POC™ devices will make this possible.
As a future development, we envisage that globally distributed Q-POC™ devices will geotag and anonymise pathogen data, then send it to the cloud for real-time disease and drug resistance monitoring.
Just as the internet has revolutionised how we share information, this global surveillance system will transform the way we share genomic data.
This data will be used to monitor the spread of antimicrobial resistance, detect and contain a novel disease outbreak, and identify suitable targets for drug development.
“Strengthening global AMR surveillance will be critical”
WHO AMR Global Report
“Strengthening global AMR surveillance will be critical”
WHO AMR Global Report
Q-POC™ will allow doctors to deliver clinical, actionable test results at the point of care.
This powerful tool will decentralise important and complex testing.
We will be able to identify any emerging threat, whether it is natural or biowarfare, and identify drug resistant markers.
Jonathan O’Halloran
CEO and Co-Founder of QuantuMDx
SHARE THIS PAGE
MENU
© QuantuMDx Group Ltd.
